AUS
NZ
UK
CA
USA
IND
Healthcare
Vita Life Sciences (ASX:VLS) Sees Market Strength Backed by Solid Fundamentals
July 29, 2025 08:27 PM AEST| By Team Kalkine MediaHighlights,Vita Life Sciences shows efficient capital usage through strong ROE,Earnings growth aligns with broader industry performance,Market movement reflects financial consistency,Vita Life Sciences (ASX:VLS) has experienced a notable uplift in it...
Algorae Pharmaceuticals Enhances AI Drug Discovery Platform with Oncology Validation Progress
July 29, 2025 05:30 PM AEST| By Team Kalkine MediaHighlights,Strategic collaboration boosts cancer-focused AI predictions,Pre-clinical trials underway for novel drug combinations,Platform upgrade targets improved accuracy and performance,Algorae Pharmaceuticals (ASX:1AI) is advancing its AI-enabled...
Prescient Strengthens Cancer Drug Pipeline With Capital Raise
July 29, 2025 05:18 PM AEST| By Team Kalkine MediaHighlights,Prescient Therapeutics completes Share Purchase Plan to fund PTX-100 development,Launches follow-on placement as part of broader capital strategy,Focus remains on advancing precision oncology and immunotherapy platforms,Prescient Therapeut...
Prescient Therapeutics Secures Funding for Phase 2 Cancer Trials
July 29, 2025 03:43 PM AEST| By Team Kalkine MediaHighlights,Prescient Therapeutics completes Share Purchase Plan to progress PTX-100,Launches placement offer to meet extended funding interest,Clinical trial targets Cutaneous T cell lymphoma with global enrolment open,Prescient Therapeutics Ltd (ASX...
Why CSL (ASX:CSL) Continues to Draw Attention in the ASX 200 Healthcare Space
July 29, 2025 10:45 AM AEST| By Team Kalkine MediaHighlights,CSL,benefits,from stable healthcare demand,Positioned across key medical sectors,Healthcare sector draws ethical-focused interest,CSL (ASX:CSL), one of Australia's most recognised biotechnology companies, has maintained a strong presence w...
Radiopharm Theranostics Advances Novel Cancer Therapy with FDA Clearance
July 28, 2025 04:32 PM AEST| By Team Kalkine MediaHighlights,FDA greenlights Phase 1 trial for RV-01,Targeting B7H3 in solid tumours with novel therapy,Strategic isotope supply boosts development pipeline,Radiopharm Theranostics (ASX:RAD) has secured a significant milestone with investigational new...
Market Nerves Ahead of Key Inflation Data and Trump’s Tariff Clock: Implications for S&P 200
July 28, 2025 04:10 PM AEST| By Team Kalkine MediaHighlights:,Wall Street closed on a new high, but caution grips Australian markets,CPI release and Trump’s tariff plans are key near-term concerns,Investors assess implications across global and local stocks,With Wall Street pushing to a fresh high l...
Cochlear (ASX:COH): Strength in Healthcare and Steady Growth within ASX 200
July 28, 2025 03:06 PM AEST| By Team Kalkine MediaHighlights,Leading global brand in hearing implant technology,Resilient demand supports consistent performance,Aligned with rising focus on ethical healthcare,Cochlear (COH), based in Sydney and established in the early 1980s, is a globally recognise...
Is ResMed (ASX:RMD) Undervalued in 2025? | All Ordinaries Healthcare Stock with Global Tech Focus
July 27, 2025 07:28 PM AEST| By Team Kalkine MediaHighlights,Global healthcare firm with strong presence in sleep and respiratory care,Combines smart hardware with SaaS-driven efficiency,Financially robust with a conservative debt profile,ResMed (RMD) is a globally recognised medical technology comp...
ASX 200 Futures Watch: Clarity Pharmaceuticals (ASX:CU6) Surges Amid Anticipated Clinical Milestone
July 27, 2025 06:21 PM AEST| By Team Kalkine MediaHighlights:,Clarity Pharmaceuticals gains momentum on the ASX,Clinical trial developments boost investor sentiment,Market attention shifts to Co-PSMA study results,ASX 200 futures,edged higher on Thursday, buoyed by strong interest in biotech counter...
Telix Pharmaceuticals (ASX:TLX) Share Slide | R&D Strategy and Revenue Guidance in ASX 200 Biotech
July 27, 2025 06:06 PM AEST| By Team Kalkine MediaHighlights,Telix reaffirms revenue guidance despite recent share movement,Rising R&D marks shift toward innovation,Illuccix and RLS remain key revenue contributors,Telix Pharmaceuticals (TLX), a key biotechnology company listed on the,ASX 200,, exper...
Has Oneview Healthcare (ASX:ONE) Moved Ahead of Its Fundamentals?
July 26, 2025 04:57 PM AEST| By Team Kalkine MediaHighlights,Revenue growth has lagged behind other healthcare service peers,Recent share momentum may not reflect underlying business pace,Caution warranted if financials don’t align with current market sentiment,Oneview Healthcare (ASX:ONE) has exper...
CSL vs Pro Medicus: Exploring Healthcare Picks from ASX 200 in 2025
July 26, 2025 02:21 PM AEST| By Team Kalkine MediaHighlights,CSL and Pro Medicus operate in distinct segments of healthcare,CSL's strengths lie in mature pharma and biotech infrastructure,Pro Medicus is known for radiology-focused software solutions,When it comes to healthcare-focused,ASX 200,stocks...
Race Oncology’s RC220 Marks Clinical Advancement in ASX Biotech Landscape
July 25, 2025 05:23 PM AEST| By Team Kalkine MediaHighlights,First clinical trial dosing of RC220 completed,Broader application explored beyond leukemias,New leadership appointments reinforce trial execution,Race Oncology Ltd (ASX:RAC) has initiated clinical dosing of its novel compound RC220, a ref...
Althea Group Holdings (ASX:AGH) Ushers in New Leadership to Strengthen Beverage Strategy
July 24, 2025 07:42 PM AEST| By Team Kalkine MediaHighlights,Leadership change announced at Althea Group Holdings,New interim head appointed with beverage industry background,Focus sharpened on expanding THC beverage segment,Althea Group Holdings (ASX:AGH), a company operating within the medicinal c...
CSL Ltd: Exploring One of the ASX 200 Healthcare Giants
July 24, 2025 06:16 PM AEST| By Team Kalkine MediaHighlights,CSL Ltd maintains strong financial fundamentals,Operates across global biopharma, flu vaccines, and kidney care,Continues to draw long-term attention among ASX 200 stocks,CSL Ltd (ASX:CSL) remains a prominent name among,ASX 200,stocks, kno...
Prescient Therapeutics Advances Cancer Drug PTX-100 Toward Next Clinical Milestone
July 24, 2025 05:41 PM AEST| By Team Kalkine MediaHighlights,PTX-100 enters Phase 2 trials targeting hard-to-treat T-cell lymphoma,Regulatory designations boost development prospects,Multiple commercialisation routes under consideration,Prescient Therapeutics (ASX:PTX) is making steady progress in i...
Prescient Therapeutics Advances PTX-100 Cancer Therapy Toward Market Readiness
July 24, 2025 10:13 AM AEST| By Team Kalkine MediaHighlights,PTX-100 progressing through Phase 2 trials,Focused on addressing rare, aggressive cancer type,Gains regulatory support for faster market access,Prescient Therapeutics (ASX:PTX) is advancing its lead therapy candidate PTX-100 through Phase...
Cochlear (ASX:COH) Growth Story: Financial Strength, Performance, and ASX 300 Presence
July 23, 2025 06:57 PM AEST| By Team Kalkine MediaHighlights,Cochlear (COH) showcases consistent revenue momentum,Trends reflect operational resilience,Strong balance sheet underscores capital stability,Cochlear (COH), a Sydney-based medical device company, continues to gain traction within the hear...
NeuroScientific Eyes Stem Cell Breakthroughs in Chronic Disease Research
July 23, 2025 05:00 PM AEST| By Team Kalkine MediaHighlights,NeuroScientific explores stem cell use for chronic conditions,Ongoing clinical trials target Crohn’s and GVHD,StemSmart therapy shows encouraging initial outcomes,NeuroScientific Biopharmaceuticals (ASX:NSB) is advancing its therapeutic pi...
Advertise your brand on Kalkine Media